Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer
NCT03461185
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
DRUG:
EGFR-TK Inhibitor
DRUG:
Anti-Angiogenic Drugs
Sponsor
Xinqiao Hospital of Chongqing